These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35261159)

  • 1. Nanoparticles-Mediated CRISPR/Cas Gene Editing Delivery System.
    Saw PE; Cui GH; Xu X
    ChemMedChem; 2022 May; 17(9):e202100777. PubMed ID: 35261159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
    Wang L; Zheng W; Liu S; Li B; Jiang X
    Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas: A powerful tool for gene function study and crop improvement.
    Zhang D; Zhang Z; Unver T; Zhang B
    J Adv Res; 2021 Mar; 29():207-221. PubMed ID: 33842017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of nanoparticles in CRISPR/Cas9-based gene therapy].
    Ma Y; Deng L; Li S
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2087-2104. PubMed ID: 35786464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
    Li X; Shi W; Geng LZ; Xu JP
    Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
    Qiu M; Glass Z; Xu Q
    Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.
    Chuang YF; Phipps AJ; Lin FL; Hecht V; Hewitt AW; Wang PY; Liu GS
    Cell Mol Life Sci; 2021 Mar; 78(6):2683-2708. PubMed ID: 33388855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing lipid nanoparticles for efficient CRISPR delivery.
    Yan J; Kang DD; Dong Y
    Biomater Sci; 2021 Sep; 9(18):6001-6011. PubMed ID: 34115079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
    Dong W; Kantor B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
    Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
    Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biogenic materials for CRISPR delivery and therapeutics.
    Yang K; Qian J; Zhang C; Wang Z; Huang Q; Shi G; Zhang Z; Yang Y; Han X
    Biomater Sci; 2023 May; 11(9):3016-3033. PubMed ID: 36897609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
    Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
    J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR Systems Suitable for Single AAV Vector Delivery.
    Stevanovic M; Piotter E; McClements ME; MacLaren RE
    Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History, evolution and classification of CRISPR-Cas associated systems.
    Agarwal N; Gupta R
    Prog Mol Biol Transl Sci; 2021; 179():11-76. PubMed ID: 33785174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.